Appropriate Biomarkers For Oxidative Stress In Patients With End Stage Renal Disease

The appropriate biomarkers for oxidative stress (OS) in patients with end stage renal disease (ESRD) are important in renal pathology. Patients (56) with ESRD were investigated (35 men and 21 women). Patients, with mean age of 45±17 years, defined education, specific HD duration and calculated body...

Full description

Bibliographic Details
Main Authors: Dejanov Petar, Dejanova Beti
Format: Article
Language:English
Published: Sciendo 2015-12-01
Series:Serbian Journal of Experimental and Clinical Research
Online Access:http://www.degruyter.com/view/j/sjecr.2015.16.issue-4/sjecr-2015-0037/sjecr-2015-0037.xml?format=INT
id doaj-10d15308012a4124b71861af385fdaf7
record_format Article
spelling doaj-10d15308012a4124b71861af385fdaf72020-11-24T21:58:27ZengSciendoSerbian Journal of Experimental and Clinical Research 1820-86652335-075X2015-12-0116428729010.1515/sjecr-2015-0037sjecr-2015-0037Appropriate Biomarkers For Oxidative Stress In Patients With End Stage Renal DiseaseDejanov Petar0Dejanova Beti1Medical Faculty in Skopje, Skopje, Former Yugoslav Republic of MacedoniaMedical Faculty in Skopje, Skopje, Former Yugoslav Republic of MacedoniaThe appropriate biomarkers for oxidative stress (OS) in patients with end stage renal disease (ESRD) are important in renal pathology. Patients (56) with ESRD were investigated (35 men and 21 women). Patients, with mean age of 45±17 years, defined education, specific HD duration and calculated body mass index (BMI), were exposed to a polysulphone type HD membrane for approximately 4 hours per HD session, 3 times per week. The control group was composed of 31 healthy volunteers. The total antioxidative capacity (TAC) and the antioxidative (AO) enzymes superoxide dismutase (SOD) and glutathione peroxidase (GPx), were assessed. Analyses included Randox Crumlin GB; lipid peroxidation (LP) using its end product, malonyldialdehyde (MDA) (fluorimetric); and a LDL-ox immunoassay (Biomedica gruppe, Vienna, Austria). The TAS was higher in ESRD patients before HD (1.63±0.1 mmol/L) compared to the control group (1.23±0.03 mmol/L).http://www.degruyter.com/view/j/sjecr.2015.16.issue-4/sjecr-2015-0037/sjecr-2015-0037.xml?format=INT
collection DOAJ
language English
format Article
sources DOAJ
author Dejanov Petar
Dejanova Beti
spellingShingle Dejanov Petar
Dejanova Beti
Appropriate Biomarkers For Oxidative Stress In Patients With End Stage Renal Disease
Serbian Journal of Experimental and Clinical Research
author_facet Dejanov Petar
Dejanova Beti
author_sort Dejanov Petar
title Appropriate Biomarkers For Oxidative Stress In Patients With End Stage Renal Disease
title_short Appropriate Biomarkers For Oxidative Stress In Patients With End Stage Renal Disease
title_full Appropriate Biomarkers For Oxidative Stress In Patients With End Stage Renal Disease
title_fullStr Appropriate Biomarkers For Oxidative Stress In Patients With End Stage Renal Disease
title_full_unstemmed Appropriate Biomarkers For Oxidative Stress In Patients With End Stage Renal Disease
title_sort appropriate biomarkers for oxidative stress in patients with end stage renal disease
publisher Sciendo
series Serbian Journal of Experimental and Clinical Research
issn 1820-8665
2335-075X
publishDate 2015-12-01
description The appropriate biomarkers for oxidative stress (OS) in patients with end stage renal disease (ESRD) are important in renal pathology. Patients (56) with ESRD were investigated (35 men and 21 women). Patients, with mean age of 45±17 years, defined education, specific HD duration and calculated body mass index (BMI), were exposed to a polysulphone type HD membrane for approximately 4 hours per HD session, 3 times per week. The control group was composed of 31 healthy volunteers. The total antioxidative capacity (TAC) and the antioxidative (AO) enzymes superoxide dismutase (SOD) and glutathione peroxidase (GPx), were assessed. Analyses included Randox Crumlin GB; lipid peroxidation (LP) using its end product, malonyldialdehyde (MDA) (fluorimetric); and a LDL-ox immunoassay (Biomedica gruppe, Vienna, Austria). The TAS was higher in ESRD patients before HD (1.63±0.1 mmol/L) compared to the control group (1.23±0.03 mmol/L).
url http://www.degruyter.com/view/j/sjecr.2015.16.issue-4/sjecr-2015-0037/sjecr-2015-0037.xml?format=INT
work_keys_str_mv AT dejanovpetar appropriatebiomarkersforoxidativestressinpatientswithendstagerenaldisease
AT dejanovabeti appropriatebiomarkersforoxidativestressinpatientswithendstagerenaldisease
_version_ 1725851950263566336